Acasti Pharma Inc.
ACST
$0.13
Change (1 day)
$3.60
Year High
$1.98
Year Low
Categories
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
P/E ratio for Acasti Pharma Inc. (ACST)
P/E ratio as of 2023: -2.56
According to Acasti Pharma Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.56. At the end of 2022 the company had a P/E ratio of -0.48.
P/E ratio history for Acasti Pharma Inc. from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.56 |
| 2022 | -0.48 |
| 2021 | -4.58 |
| 2020 | -3.62 |
| 2019 | -1.25 |
| 2018 | -10.18 |
| 2017 | -9.02 |
| 2016 | 0.00 |
| 2015 | -4.64 |
| 2014 | -55.18 |
| 2013 | -11.36 |
| 2012 | -25.39 |
| 2011 | -16.79 |
| 2010 | -3.76 |
| 2009 | -2.73 |